Over the long, checkered history of weight-loss drugs, a safe and highly effective medication
has been the elusive holy grail. The handful of drugs currently approved for long-term …

This past June, the US Food and Drug Administration approved semaglutide, a glucagon-
like peptide 1 receptor agonist marketed as Wegovy, for chronic weight management based …

Overweight and obesity are one of the most relevant health factors; according to the WHO,
39% of people globally are overweight and 13% obese. 1 Body weight loss of 3%–5% has …

Semaglutide 2· 4 mg once weekly, an anti-obesity medication now submitted to regulators
across the USA and Europe, is generating much excitement and attention about the amount …

The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous
semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term …

Obesity is a chronic, recurring, progressive disease and a major public health problem
associated with several other diseases that lead to disability, morbidity, and mortality. The …

Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

Background Management guidelines for obesity suggest maintaining a minimum of 5% body
weight reduction to help prevent or lower the risk of developing conditions such as …

Objective: The obesity epidemic is a public health concern, warranting further research into
pharmacological treatments for weight management (WM) as an adjunct to lifestyle …

Objective The obesity epidemic is a public health concern, warranting further research into
pharmacological treatments for weight management (WM) as an adjunct to lifestyle …